Group 1 - Multiple Wall Street firms have updated their investment ratings and target prices for Henry Schein, Inc. (HSIC.OQ) as of February 26, 2026 [1] - Morgan Stanley analyst Erin Wright maintains a sell rating, raising the target price from $58 to $61 [1] - JPMorgan analyst John Stansel maintains a buy rating, increasing the target price from $78 to $92 [1] - Bank of America analyst Allen Lutz keeps a buy rating, raising the target price from $87 to $96 [1] - UBS analyst Kevin Caliendo maintains a hold rating, increasing the target price from $79 to $87 [1] - Mizuho Securities analyst Steven Valiquette maintains a hold rating, raising the target price from $81 to $88 [1] - Leerink Partners analyst Michael Cherny maintains a hold rating with a target price of $87 [1] Group 2 - As of February 26, 2026, Henry Schein, Inc. (HSIC.OQ) has a latest stock price of $81.47, down 0.54% on that day [2] - The stock has increased by 6.08% over the past five days, with a total market capitalization of approximately $9.591 billion [2] - The medical sales sector rose by 1.05% on the same day, while the Dow Jones index increased by 0.03% and the Nasdaq decreased by 1.18% [2]

Stock Performance - Akso Health Group's stock price experienced significant fluctuations in January 2026, with a drop of 5.49% on January 3, a decline of 6.25% on January 6, and an increase of 7.52% on January 9. The trading volume and turnover rate were generally low, indicating limited market participation [1]. Financial Performance - As of January 2026, the company's latest financial report shows revenue of $14.8 million, a net loss of $135 million, earnings per share of -$0.47, and a negative gross margin. Currently, no institutions have issued rating recommendations for the stock [2]. Industry Policy and Environment - The medical sales industry, to which the company belongs, showed minimal overall volatility in January 2026, with price fluctuations within ±1.5%. However, there was significant differentiation among individual stocks. The company's business relies on medical device sales, which are heavily influenced by policies, demand, and competition [3]. Future Development - The company's ongoing losses and weak profitability may affect investor confidence. Additionally, low liquidity could amplify stock price volatility risks [4].

Core Viewpoint - Cardina Health (CAH.US) reported revenue growth in its recent earnings report, leading to an increase in stock price and several institutions raising their target prices [1] Group 1: Earnings Performance - For the second quarter of fiscal year 2026, the company reported revenue of $65.627 billion, a year-over-year increase of 18.75% [2] - Net profit reached $467 million, reflecting a 16.75% year-over-year growth, primarily driven by the pharmaceutical distribution business [2] - Following the earnings release, the stock price experienced a fluctuation of 6.91% over the week, peaking at $230.81 on February 6 and dipping to $212.03 on February 5 [2] Group 2: Institutional Opinions - TD Cowen maintained a "Buy" rating on February 11, 2026, raising the target price from $233 to $251 based on better-than-expected earnings and industry outlook [3] - Among 20 institutions that provided insights in February, 80% rated the stock as "Buy" or "Hold," with an average target price of $251.13 [3] - The overall healthcare sales sector saw a rise of 1.05% during the same period [3] Group 3: Market Activity - On the earnings release date (February 5), trading volume reached 3.58 million shares, but decreased to 126,800 shares by February 11, indicating a drop in trading activity [4] - Prior to the earnings report, from November to December 2025, the company experienced several days of significant trading volume increases, such as a 12.24% surge on November 24 [4]

Group 1 - The core viewpoint is that Akso Health Group has not disclosed any significant future events, such as new product launches or strategic partnerships, and is experiencing significant stock price volatility along with ongoing losses [1] Group 2 - Recent stock performance shows that Akso Health Group's stock price experienced multiple significant fluctuations in January 2026, with declines on January 3 and January 6, followed by an increase on January 9. The trading volume and turnover rate are generally low, indicating limited market participation [2] Group 3 - As of the latest financial report in January 2026, the company reported revenue of $14.8 million, a net loss of $135 million, earnings per share of -$0.47, and a negative gross margin. Currently, no institutions have issued rating recommendations for the stock [3] Group 4 - The medical sales industry, to which the company belongs, showed overall minor fluctuations in January 2026, but there is significant differentiation among individual stocks. The company's business relies heavily on medical device sales, which are greatly influenced by policies, demand, and competition [4] Group 5 - The company's ongoing losses and weak profitability may affect investor confidence. Additionally, low liquidity could amplify stock price volatility risks [5]

Core Viewpoint - Henry Schein Inc. (HSIC.OQ) has experienced a strong stock price increase and has broken through key technical levels, driven by market trading sentiment, with a notable 11.34% increase over a five-day period from February 4 to February 10, 2026 [1] Stock Performance - As of February 12, 2026, Henry Schein's stock price is reported at $79.81, reflecting a daily decrease of 2.30% with a volatility of 3.91% - The stock has shown a cumulative increase of 3.65% over the past five days, 4.65% over the past 20 days, and a year-to-date increase of 5.59%, indicating recent fluctuations compared to the previous closing price of $81.44 on February 10 [2] - On February 12, the trading volume amounted to approximately $51.91 million with a volume ratio of 0.78; the price-to-earnings (TTM) ratio stands at 25.18 and the price-to-book ratio at 2.80, while the healthcare sales sector saw a slight increase of 0.14% [2] Financial Background - The financial report for the third quarter of fiscal year 2025 (ending September 27, 2025) indicates a year-over-year revenue growth of 5.20% and a net profit increase of 2.02%, with a gross margin of 28.69%, although this data does not reflect recent events [3]

Group 1 - The core viewpoint of the article highlights the strong performance of Henry Schein, Inc. (HSIC.OQ), with its stock price reaching $81.69 on February 11, 2026, marking a 0.83% increase and breaking a 60-day high [1] - The stock has shown a robust upward trend, with a cumulative increase of 11.34% over the five days leading up to February 10, 2026, and continued gains on February 11, supported by a trading volume of approximately $111 million [1] - The healthcare sales sector also experienced a rise of 1.83%, contributing to the overall strength of the market [1] Group 2 - For the third quarter of fiscal year 2025, ending September 27, 2025, the company reported a revenue growth of 5.20% year-over-year, with a net profit increase of 2.02% [1] - The gross margin stood at 28.69%, and the return on equity (ROE) reached 11.39%, indicating stable financial performance despite moderate profit growth [1] - The stock price broke through a key resistance level on February 11, with a five-day increase of 8.54% and a 20-day increase of 7.74%, reflecting bullish technical indicators and attracting trend-following investments [1]

Group 1 - The stock price of 1药网 (YI.OQ) fell by 5.26% on February 11, 2026, closing at $7.57 [1] - The stock opened at $7.91, reached a high of $7.91, and a low of $7.43, with a trading range of 6.01% [1] - The trading volume was 5,701 shares, with a total transaction value of $43,781, resulting in a turnover rate of 0.07% [1] Group 2 - The healthcare sales sector in the US stock market saw a slight increase of 0.47% on the same day [2] - The major US indices, Dow Jones and Nasdaq, experienced minor declines of 0.02% and 0.04% respectively, indicating that the individual stock underperformed compared to the sector and the overall market [2] - The A-share pharmaceutical e-commerce sector (code: 02250004) declined by 0.59%, with a net outflow of approximately 1.108 billion yuan, reflecting overall pressure in the pharmaceutical e-commerce field [2]

Group 1 - The stock price of Henry Schein Inc. (HSIC.OQ) has shown strong performance driven by market trading sentiment, with a closing price of $81.44 as of February 10, 2026 [1] - The stock has experienced a cumulative increase of 11.34% over the past five days and 6.97% over the past twenty days, indicating a strong short-term trend [2] - Year-to-date, the stock has risen by 7.75%, reflecting its resilience compared to the medical sales sector, which has declined by 2.05% during the same period [2] Group 2 - On February 10, the stock price increased by 1.67%, reaching a high of $81.67, with a trading volume of 429,174 shares and a transaction value of approximately $34.59 million [2] - The stock's price-to-earnings (P/E) ratio is 25.69, and the price-to-book (P/B) ratio is 2.85, indicating its valuation metrics in the market [2] - The trading activity reflects a moderate level of engagement, with a volume ratio of 0.57 [2]

Core Insights - Cardina Health reported Q2 revenue of $65.627 billion for fiscal year 2026, representing an 18.75% year-over-year increase; net profit reached $4.67 billion, up 16.75% year-over-year, driven primarily by the pharmaceutical distribution business, although gross margin was 3.52% and net margin was 0.71%, reflecting industry characteristics [1] Institutional Views - TD Cowen maintained a "Buy" rating for Cardina Health on February 11, 2026, raising the target price from $233 to $251 based on better-than-expected performance and industry outlook; among 20 institutions covering the stock in February, 80% rated it as "Buy" or "Hold," with an average target price of $251.13 [2] Recent Events - The financial report was disclosed before the market opened on February 5, 2026; TD Cowen raised the target price on February 11, coinciding with a 1.05% increase in the overall healthcare sales sector [3] Stock Performance - Over the past 7 days (February 5 to 11), the stock price fluctuated by 6.91%, with a high of $230.81 on February 6 and a low of $212.03 on February 5; the closing price on February 11 was $221.14, with a single-day increase of 0.39% and a volatility of 1.15%; trading volume peaked at 3.58 million shares on February 5, dropping to 126,790 shares by February 11, indicating a rise and subsequent decline in trading activity [4]